In the treatment of estrogen receptor positive (ER+) breast cancer, both of these drugs restrain fertility by suppressing the release of luteinizing hormone (LH), one of the contraceptive hormones imperative in ovulation [77, 78]. This evidence concerns the gene PLOD1 and breast carcinoma.